Product name Donepezil
Appearance: White or off-white crystalline powder
CAS NO. 120014-06-4
Molecular Formula C24H29NO3
Molecular Weight 379.49200
Melting point 207ºC
Boiling point 527.9ºC at 760mmHg
Flash point 273.1ºC
Donepezil hydrochloride is a therapeutic treatment of Alzheimer's drugs
White or almost white crystalline powder
A: By IR, To match with working standard
B: By UV, To match with working standard.
Residue on ignition
Mild or moderate Alzheimer-type dementia treatment.
Donepezil hydrochloride is a long-acting Alzheimer's disease (AD) in the symptomatic treatment drugs.
AD is a kind of memory loss as the main performance, accompanied by other cognitive impairment of acquired intelligence decline. Nearly 30 years of research show: AD progressive degeneration of cholinergic neurons is memory loss, disorientation, personality changes and behavioral reasons,such cholinergic theory has been confirmed by histological study. Donepezil hydrochloride is a second-generation cholinesterase (ChE) inhibitor, its therapeutic effect is reversibly inhibiting acid hydrolysis of acetylcholine acetylcholinesterase (AchE) caused by increased content of acetylcholine receptor sites.
Donepezil may have other mechanisms, including the disposal of the direct effect of the peptide,neurotransmitter receptors, or Ca2 + channels.
Donepezil hydrochloride selection of AchE affinity than to butyrylcholinesterase (BchE) 1250 times stronger,it can inhibit the brain tissue ChE, but on the heart (myocardium) or small intestine (smooth) had no effect,probably on the chest organization (rhabdomyosarcoma) role; on the central nervous toxicity than tacrine.
1. adult / elderly: initial treatment dosage 5mg / day (day 1). The product should be orally at bedtime at night.
Doses of 5mg / day should be maintained at least - months to evaluate early clinical response, and donepezil hydrochloride reach steady-state plasma concentrations. After using 5mg / day treatment a month, making clinical evaluation may be the product of the dose to 10mg / day (day 1). The maximum recommended dose is 10mg.
Greater than 10mg / day dose clinical trials have not done. We did not conduct placebo-controlled clinical trials with more than six months. After stopping treatment, the efficacy of the product gradually diminishes. Discontinuation of treatment no rebound phenomenon.
2. liver and kidney damage: For mild to moderate renal and hepatic dysfunction, donepezil hydrochloride elimination is not affected, so these patients can use a similar dose schedule.